Ursprung des Netzwerks ersten Grades von William Parish
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
KWS BioTest Ltd.
KWS BioTest Ltd. Pharmaceuticals: MajorHealth Technology KWS BioTest Ltd. provides preclinical pharmacology and drug development for human diseases. Its capabilities include clinical biomarkers, cell biology, bioanalytical services, in vivo pharmacology, vaccine development. The company was founded by Williams A. Neil and Trevor Langley in 2004 and is headquartered in Bristol, the United Kingdom.
6
| Subsidiary | Pharmaceuticals: Major | 6 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von William Parish
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Wyeth Corp.
Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Pharmaceuticals: Major | Corporate Officer/Principal | |
PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
EVOTEC SE | Pharmaceuticals: Major | Corporate Officer/Principal | |
NextPharma Technologies Ltd.
NextPharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology NextPharma Technologies, In. develops, manufactures, packages, and distributes pharmaceutical products and formulations. The firm focuses on lyophilization, sterile fill finish and pellet technologies, and in product manufacturing including cyotoxics, hormones, penicillins, cephalosporins, and controlled drugs. The company was established on October 27, 2000 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Corporate Officer/Principal | |
The University of Edinburgh | College/University | Doctorate Degree | |
University of Bristol | College/University | Corporate Officer/Principal | |
Cranfield University | College/University | Masters Business Admin | |
London Business School | College/University | Undergraduate Degree | |
King's College London | College/University | Undergraduate Degree | |
Wyvern Asset Management Ltd.
Wyvern Asset Management Ltd. Investment ManagersFinance Wyvern Asset Management Ltd. (Wyvern Asset Management) is an independent venture capital firm founded in 1999. The firm is headquartered in Bristol, United Kingdom. | Investment Managers | Chief Executive Officer | |
JPT Peptide Technologies GmbH
JPT Peptide Technologies GmbH Medical SpecialtiesHealth Technology JPT Peptide Technologies GmbH provides innovative peptide based products and services for vaccine development, immune monitoring and peptide biomarker discovery. The firm’s products include custom peptides, modified & labeled peptides, clinical peptides, stable isotope-labeled peptides, SPOT peptides, immunogenic peptides, peptide libraries, peptide pools, peptide microarrays, peptide ELISA, enzyme profiling and epitope discovery service. The company was founded in 2004 and is headquartered in Berlin, Germany. | Medical Specialties | Chief Executive Officer | |
BIONTECH SE | Biotechnology | Chief Operating Officer | |
Manchester Business School | College/University | Masters Business Admin | |
UCB Celltech
UCB Celltech BiotechnologyHealth Technology Part of UCB SA, UCB Celltech is a British company that develops novel therapeutic products for humans. The company is based in Slough, UK and was founded in 2006. | Biotechnology | Corporate Officer/Principal | |
Azellon Ltd.
Azellon Ltd. Miscellaneous Commercial ServicesCommercial Services Azellon Ltd. develops stem cell therapy for the repair of avascular meniscal tears. The firm's meniscal repair technology combines bone marrow stem cells with a special membrane that helps to deliver the cells into the injured site. The company was founded by Anthony Hollander and Troels Jordansen in 2007 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Chairman | |
ELECTROCORE, INC. | Medical Specialties | Sales & Marketing | |
Mann Bioinvest Ltd.
Mann Bioinvest Ltd. Financial ConglomeratesFinance Mann Bioinvest Ltd. invests in the life science sector. The company was founded by James Mellon in 2012 and is headquartered in Douglas, the United Kingdom. | Financial Conglomerates | Director/Board Member | |
Southampton Business School | College/University | Undergraduate Degree | |
Medicines Discovery Catapult Ltd.
Medicines Discovery Catapult Ltd. Miscellaneous Commercial ServicesCommercial Services Medicines Discovery Catapult Ltd. is a not-for-profit organization that enables the community to accelerate innovative drug discovery. The private company is based in Macclesfield, UK, and has subsidiaries in the United Kingdom. The British company focuses on pioneering the next generation of medicine discovery techniques and technologies by validating new ways of discovering medicines and driving key talent and expertise across the sector. The CEO of the company is Chris Molloy. | Miscellaneous Commercial Services | Chairman | |
Aicuris Anti-Infective Cures AG
Aicuris Anti-Infective Cures AG Miscellaneous Commercial ServicesCommercial Services Part of Santo Holding (Deutschland) GmbH, Aicuris Anti-Infective Cures AG aims to discover, develop, and deliver innovative, anti-viral drugs to immunocompromised patients aiming to prevent severe condition and life-threatening diseases. The company is based in Wuppertal, Germany. Aicuris has developed a commercial drug as well as pipeline of clinical-stage and pre-clinical anti-viral candidates. Its lead product Prevymis® (letermovir), a first-in-class non-nucleoside cytomegalovirus (CMV) inhibitor, was licensed to MSD and is commercialized for the prevention of human CMV infections in immunocompromised patients who underwent an allogeneic hematopoietic stem cell transplantation or kidney transplantation. Aicuris wholly owned product candidate, Pritelivir, targeting resistant herpes simplex virus (HSV) infections in immunocompromised patients, is in phase 3 clinical development. The German company was founded in 2006 by Helga Rübsamen-Schaeff. Larry G. Edwards has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Director/Board Member | |
PHMR Ltd.
PHMR Ltd. Information Technology ServicesTechnology Services Part of UDG Healthcare Ltd. (Dublin), PHMR Ltd. is a healthcare consulting British company that specializes in insight-enabled pricing and market access approaches to ensure successful product launch and life-cycle management. The company is based in London, UK. The company helps its clients in the healthcare industries build value for their products by using academically-proven analytical methods to find and form clinical, economic, and humanistic evidence. PHMR is an international team of highly qualified health economists and research scientists. The company was founded by Mark Ratcliffe, who has been the CEO since incorporation. PHMR was acquired by UDG Healthcare Ltd. (Dublin) on January 26, 2021 for $43.75 million. | Information Technology Services | Chairman | |
Anauel LLP | Corporate Officer/Principal |
Statistik
International
Vereinigtes Königreich | 18 |
Vereinigte Staaten | 5 |
Deutschland | 5 |
Sektoral
Health Technology | 11 |
Consumer Services | 8 |
Finance | 4 |
Commercial Services | 4 |
Technology Services | 2 |
Operativ
Corporate Officer/Principal | 14 |
Undergraduate Degree | 4 |
Director/Board Member | 4 |
Chief Executive Officer | 3 |
Chairman | 3 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Sean Marett | 15 |
Andrew Allars | 7 |
Sue Sundstrom | 3 |
Iain Strickland | 3 |
Robin Brown | 2 |
Neil A. Williams | 1 |
- Börse
- Insiders
- William Parish
- Unternehmensverbindungen